NovaSight
NovaSight develops eye-tracking-based vision care solutions for children, combining eye tracking technology and data analytics to revolutionize pediatric vision care. The company's two flagship products are CureSight, an FDA-cleared and CE-marked at-home amblyopia treatment system designed to replace traditional eye patching, and TrackSight, a software-based solution for myopia prevention and vision health…
Funding snapshot
About
NovaSight develops eye-tracking-based vision care solutions for children, combining eye tracking technology and data analytics to revolutionize pediatric vision care. The company's two flagship products are CureSight, an FDA-cleared and CE-marked at-home amblyopia treatment system designed to replace traditional eye patching, and TrackSight, a software-based solution for myopia prevention and vision health monitoring. CureSight provides remote digital amblyopia treatment through a patented approach that uses eye tracking to monitor and modify content displayed to each eye individually, enabling dichoptic treatment without the social stigma and discomfort of physical patches. TrackSight offers myopia management and prevention through software-based vision health monitoring. NovaSight's technology utilizes optical IR sensors that track and record momentary gaze position 90 times per second, proprietary ActiveSight glasses providing remote-controlled eye occlusion with distance and tilt measurements, and AI-powered big data analytics that correlate eye patterns to create vision population norms for clinical assessment and treatment decisions. The platform is designed specifically for children, with screening, assessment, and treatment delivered through fun, entertaining, and child-friendly activities that maximize comfort and engagement. The objective measurement approach does not rely on patient cooperation or operator skills, raising the eye-care standard with greater accuracy and repeatability than legacy solutions while reducing chair time and accelerating treatment. Founded in 2016 and headquartered in Lod, Israel, with a US office in Lewes, Delaware, NovaSight has raised $20.0M in Series B funding from investors including Rimonci and EIT Health.
Business model
Eye Tracking > Applications > Healthcare,
Healthcare IT > Provider > Clinical Operations > Decision Support > Diagnosis > Diagnostics and Assessment Tests > Cognitive Assesment > Eye tracking,
Neurology > Medical Devices > Screening Devices > Eye Tracking,
Ophthalmology > Medical Devices > Imaging > Pediatric Vision Screening,
Pediatrics > Medical Devices > Screening > Ophthalmology
Team background
College Wise > University of Cambridge, Technion Israel Institute Technology
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.